Table 3.
Correlations between changes in β-OHB, blood pressure and vascular parameters
Empa Δβ-OHB | Placebo Δβ-OHB | |
---|---|---|
Δ Resting peripheral systolic BP | r = 0.458 | r = − 0.336 |
p = 0.011 | p = 0.203 | |
Δ Resting peripheral diastolic BP | r = 0.365 | r = − 0.162 |
p = 0.047 | p = 0.548 | |
Δ Resting peripheral pulse pressure | r = 0.471 | r = − 0.087 |
p = 0.009 | p = 0.749 | |
Δ Central systolic BP | r = 0.470 | r = − 0.413 |
p = 0.009 | p = 0.112 | |
Δ Central pulse pressure | r = 0.391 | r = − 0.266 |
p = 0.033 | p = 0.320 | |
Δ Forward pulse pressure height | r = 0.451 | r = 0.086 |
p = 0.012 | p = 0.752 | |
Δ Resting pulse pressure height | r = 0.217 | r = − 0.342 |
p = 0.250 | p = 0.194 | |
Δ Systolic 24 h ambulatory BP | r = 0.321 | r = 0.141 |
p = 0.069 | p = 0.630 | |
Δ Diastolic 24 h ambulatory BP | r = 0.516 | r = 0.195 |
p = 0.002 | p = 0.504 | |
Δ Heart rate | r = 0.188 | r = 0.439 |
p = 0.320 | p = 0.089 |
Δ: change between baseline and after 12 weeks of treatment, β-OHB: β-hydroxybutyrate; empa: empagliflozin; BP: blood pressure